<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081336</url>
  </required_header>
  <id_info>
    <org_study_id>022021</org_study_id>
    <nct_id>NCT05081336</nct_id>
  </id_info>
  <brief_title>Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry</brief_title>
  <acronym>RS-ACS</acronym>
  <official_title>Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Clinical Centre of Republic of Srpska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Clinical Centre of Republic of Srpska</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol&#xD;
      (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS).&#xD;
      However, the data coming from the real-world setting are limited. Therefore, the aim of the&#xD;
      study is to assess the association between LDL-C changes with prognosis in patients who&#xD;
      survive ACS.&#xD;
&#xD;
      Patients with ACS will be followed for mortality and major events for at least 1 year.&#xD;
      Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The&#xD;
      associations between quartiles of LDL-C change and therapy intensity with outcomes will be&#xD;
      investigated using adjusted Cox regression analyses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Cardiovascular Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause death, Acute Coronary Syndrom, Need for Myocardial Revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL reduction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>High-intensity statin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>High-intensity statin plus ezetimib</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>High-intensity statin plus ezetimib plus PCSK9 inhibitor</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Statin +/- ezetimib +/- Alirocumab</description>
    <arm_group_label>High-intensity statin</arm_group_label>
    <arm_group_label>High-intensity statin plus ezetimib</arm_group_label>
    <arm_group_label>High-intensity statin plus ezetimib plus PCSK9 inhibitor</arm_group_label>
    <other_name>Ezetimib</other_name>
    <other_name>Alirocumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients presented with acute coronary syndrome in one of hospitals in Republic&#xD;
        of Srpska&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute coronary syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bojan M Stanetic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinical Centre of the Republic of Srpska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bojan M Stanetic, MD, PhD</last_name>
    <phone>0038765614340</phone>
    <email>bojan.stanetic@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamara S Kovacevic-Preradovic, MD, PhD</last_name>
    <email>tamara.preradovic@medicolaser.info</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <state>Republic Of Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan M Stanetic, MD, PhD</last_name>
      <phone>0038765614340</phone>
      <email>bojan.stanetic@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Clinical Centre of Republic of Srpska</investigator_affiliation>
    <investigator_full_name>Bojan Stanetic</investigator_full_name>
    <investigator_title>Assistant Prof. Bojan Stanetic, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

